Who We Are
Corporate Profile
Oranda Therapeutics is a rare disease company dedicated to securing sustainable access to established and innovative new medicines across Europe.
Our Strategy
CorporateStrategy
Commercialise established rare disease medicines
- Portfolio of 8 generic rare disease medicines
- First revenues expected Q2 2026
- Revenue target >€50m by 2028
In-license, co-develop and commercialise novel rare disease assets
- Working to secure a pipeline of innovative medicines through partner engagement and active asset evaluation
- Focus on rare diseases with high unmet need
- Partnership-led approach to de-risk development
OTD-NP-GBR-00006 | March 2026